platelet transfusion information from trusted sources:
REGRANEX Gel contains becaplermin, a recombinant human platelet-derived growth factor (rhPDGF-BB) for topical administration. Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet-derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds. Becaplermin Concentrate is produced by Novartis Vaccines and Diagnostics, Inc. and supplied to OMJ Pharmaceuticals under a shared manufacturing arrangement. REGRANEX Gel is a non-sterile, low bioburden, preserved, sodium carboxymethylcellulose-based (CMC) topical gel, containing the active ingredient becaplermin and the following inactive ingredients: sodium chloride, sodium acetate trihydrate, glacial acetic acid, water for injection, and methylparaben, propylparaben, and m-cresol as preservatives and l-lysine hydrochloride as a stabilizer. Each gram of REGRANEX Gel contains 100 &micro,g of becaplermin. REGRANEX (becaplermin) Gel is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. When used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control, REGRANEX Gel increases the incidence of complete healing of diabetic ulcers.
Thrombocyte is the medical term for platelet. Thrombocytopenia means a lower platelet count in the blood compared to the normal range. Thrombocytosis refers to a greater number of platelets compared to the normal range.
Plateletpheresis - Wikipedia, the free encyclopedia
Platelet transfusions are traditionally given to those undergoing chemotherapy for leukemia, multiple myeloma, those with aplastic anemia, AIDS, ...
Low-Dose Platelet Transfusion May Increase Number of Transfusions ...
by L Barclay - 2010
by DF Stroncek - 2007 - Cited by 57 - Related articles
Clinical and laboratory aspects of platelet transfusion therapy
Aug 10, 2010 ... Platelets play a vital role in the maintenance of normal hemostatic activity. For patients with thrombocytopenia or impaired platelet ...
Low-Dose Platelet Transfusions Deemed Safe - US News and World Report
Feb 17, 2010 ... Study finds no bleeding risk in practice that could stretch limited supplies.
Platelet Transfusion in Acute Intracerebral Hemorrhage - Full Text ...
Jun 12, 2008 ... To prove the efficacy and safety of platelet transfusion for prevention of hematoma growth in patients who were stricken by acute ...
Type 2 Heparin-induced Thrombocytopenia
Heparin-induced thrombocytopenia (throm-bo-seye-to-PEE-nee-ah) is a condition where there are too few platelets in the blood after receiving heparin. Heparin is a medicine that is usually used to prevent or treat a thrombosis (blood clot) or blood clotting disorder. Platelets are blood cells that help stop bleeding by sticking together to form a clot. Heparin-induced thrombocytopenia, also called HIT, may be mild (Type 1) or severe (Type 2). Type 1 HIT does not produce signs and symptoms, and is not due to a problem with the immune system. Type 2 HIT is due to an immune system problem, is often life-threatening, and needs immediate treatment. In Type 2 HIT, clots may form in blood vessels and cause serious problems in the heart, limbs, brain, and lungs. Usually in HIT, the platelet count (number of platelets) decreases 5 to 10 days after heparin was given. With rapid-onset HIT, the platelet count decreases within minutes to hours after receiving heparin. With delayed-onset HIT, a decrease in the platelet count may happen up to 100 days after heparin was given. Diagnosing and treating HIT as soon as possible may relieve symptoms and prevent serious, life-threatening complications.
ReoPro Abciximab - Abciximab, ReoPro, is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. Abciximab also binds to the vitronectin ((alpha) v(beta)3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.